Evidence map›Paper›PMID 39607395›Full record

ArticleEpilepsia2025

Ablation of CCL17-positive hippocampal neurons induces inflammation-dependent epilepsy.

Judith Eberhard, Lukas Henning, Lorenz Fülle, Konrad Knöpper, Jana Böhringer, Frederike J Graelmann, Lea Hänschke, Julia Kenzler, Frederic Brosseron, Michael T Heneka and 7 more

Abstract read
In one paragraph

Article in Epilepsia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Judith EberhardImmunology & Environment, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany.ORCID https://orcid.org/0009-0000-3445-6397
Lukas HenningInstitute of Cellular Neurosciences, Medical Faculty, University of Bonn, Bonn, Germany.ORCID https://orcid.org/0000-0003-4749-5162
Lorenz FülleImmunology & Environment, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany.ORCID https://orcid.org/0000-0003-2087-2984
Konrad KnöpperImmunology & Environment, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany.ORCID https://orcid.org/0000-0003-2076-2160
Jana BöhringerImmunology & Environment, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany.
Frederike J GraelmannImmunology & Environment, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany.ORCID https://orcid.org/0000-0002-6265-3547
Lea HänschkeMolecular Developmental Biology, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany.ORCID https://orcid.org/0000-0003-3964-6581
Julia KenzlerInstitute of Cellular Neurosciences, Medical Faculty, University of Bonn, Bonn, Germany.
Frederic BrosseronGerman Center for Neurodegenerative Diseases, Bonn, Germany.ORCID https://orcid.org/0000-0003-3137-7516
Michael T HenekaGerman Center for Neurodegenerative Diseases, Bonn, Germany.ORCID https://orcid.org/0000-0003-4996-1630
Ana I DomingosDepartment of Physiology, Anatomy, and Genetics, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-7938-4814
Stefanie EyerichInstitute for Medical Microbiology, Immunology, and Hygiene, Technical University of Munich, Munich, Germany.ORCID https://orcid.org/0000-0002-1166-2355
Matthias LochnerInstitute for Medical Microbiology, Immunology, and Hygiene, Technical University of Munich, Munich, Germany.ORCID https://orcid.org/0000-0002-7979-5613
Heike WeighardtImmunology & Environment, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany.ORCID https://orcid.org/0000-0002-3810-5890
Peter BednerInstitute of Cellular Neurosciences, Medical Faculty, University of Bonn, Bonn, Germany.ORCID https://orcid.org/0000-0003-0090-7553
Christian SteinhäuserInstitute of Cellular Neurosciences, Medical Faculty, University of Bonn, Bonn, Germany.ORCID https://orcid.org/0000-0003-2579-8357
Irmgard FörsterImmunology & Environment, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany.ORCID https://orcid.org/0000-0002-7644-5642

Funding

The next iteration of the AMP-T2D Knowledge PortalUM1DK105554 · NIDDK · BROAD INSTITUTE, INC. · PI BOEHNKE, MICHAEL L, BURTT, NOEL P · 2020 to 2025
$18.5M
Biotechnology and Biological Sciences Research Council BBSRC- BB/Y006488/1Deutsche Forschungsgemeinschaft 194445620Deutsche Forschungsgemeinschaft 390873048Deutsche Forschungsgemeinschaft STE 552/9Deutsches Zentrum für Neurodegenerative ErkrankungenEuropean Research Council ERC-2017 COG 771431NIDDK NIH HHS UM1 DK105554NIH HHS NIF-NIDDK-AMP-CMD- 2UM1DK105554Pfizer ASPIRE Obesity award 70591281
6 · The paper itself

Abstract

objectiveNeuronal cell death and neuroinflammation are characteristic features of epilepsy, but it remains unclear whether neuronal cell death as such is causative for the development of epileptic seizures. To test this hypothesis, we established a novel mouse line permitting inducible ablation of pyramidal neurons by inserting simian diphtheria toxin (DT) receptor (DTR) cDNA into the Ccl17 locus. The chemokine CCL17 is expressed in pyramidal CA1 neurons in adult mice controlling microglial quiescence.

methodsSeizure activity in CCL17-DTR mice was analyzed by electroencephalographic recordings following treatment with DT for 3 consecutive days. Neuroinflammation and neuronal cell death were evaluated by (immuno)histochemistry. Pharmacological inhibition of TNFR1 signaling was achieved by treatment with XPro1595, a dominant-negative inhibitor of soluble tumor necrosis factor.

resultsNeuronal cell death was detectable 7 days (d7) after the first DT injection in heterozygous CCL17-DTR mice. Spontaneous epileptic seizures were observed in the vast majority of mice, often with an initial peak at d6-9, followed by a period of reduced activity and a gradual increase during the 1-month observation period. Microglial reactivity was overt from d5 after DT administration not only in the CA1 region but also in the CA2/CA3 area, shortly followed by astrogliosis. Reactive microgliosis and astrogliosis persisted until d30 and, together with neuronal loss and stratum radiatum shrinkage, reflected important features of human hippocampal sclerosis. Granule cell dispersion was detectable only 3 months after DT treatment. Application of XPro1595 significantly reduced chronic seizure burden without affecting the development of hippocampal sclerosis. SIGNIFICANCE: In conclusion, our data demonstrate that sterile pyramidal neuronal death is sufficient to cause epilepsy in the absence of other pathological processes. The CCL17-DTR mouse line may thus be a valuable model for further mechanistic studies on epilepsy and assessment of antiseizure medication.

Indexed as

EpilepsyHippocampusNeuronsPyramidal CellsAnimalsCell DeathDisease Models, AnimalElectroencephalographyMaleMiceMice, Inbred C57BLMice, TransgenicMicrogliaastrogliosisdiphtheria toxinmicrogliosisneurodegenerationXPro1595

Identifiers

PMID39607395
PMCPMC11827734

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.